Pharmacodynamics & Reaction Kinetics

← Back to Domain-Specific Families

Abstractions about efficacy, agonism, antagonism, enzyme effects, elimination, metabolic inactivation, kinetic laws, and competing chemical reactions.

12 abstractions in this family — domain-specific abstractions that sit near one another in structural-signature space (k-means over structural-signature embeddings). Each is shown with its short description.

• Efficacy — Separate the maximum effect a drug can produce at its target under full engagement (the ceiling, E_max) from the dose needed to approach it (potency, EC50), rooting that ceiling in the agent's intrinsic activity so a ceiling problem cannot be fixed by escalation.
• Elimination Pathway — Classify a drug or toxin by the dominant biochemical route through which the body removes it — hepatic metabolism, renal excretion, or a minor exit — so that clearance rate, interaction risks, and toxicity failure modes can be read off the route rather than memorized per substance.
• Enzyme Induction — The phenomenon in which a xenobiotic binds a nuclear receptor and raises transcription of specific metabolizing enzymes, enlarging the catalytic pool over days so it clears itself and every co-substrate sharing those isoforms faster.
• Enzyme Inhibition — A small molecule slows an enzyme by occupying or distorting its catalytic site, and the binding mode it uses fixes how reversible, surmountable, and durable the block will be.
• Inverse Agonist — A ligand that binds a receptor with constitutive activity and selectively stabilizes its inactive conformation, driving output below the unliganded baseline — occupying the negative end of a signed efficacy axis, distinct from an antagonist that merely blocks.
• Kinetics — Describe how fast a chemical system moves among states by relating each species' rate of change to concentrations, temperature, and catalysts through rate laws — keeping the rate-and-path question separate from the thermodynamic endpoint the system is approaching.
• Metabolic Inactivation — The enzymatic transformation of a biologically active substance into a less-active product that ends its effect — organised into phase-I functionalisation and phase-II conjugation, it sets a drug's half-life and makes interactions and variability a bookkeeping question over shared enzymes.
• Michaelis–Menten Kinetics — An initial-rate enzyme-kinetics regime in which a variable substrate drives a rectangular-hyperbolic rate toward a limiting value V, with Km marking the substrate concentration at half that limit.
• Partial Agonist — A ligand that binds and activates a receptor but with intrinsic efficacy between zero and one, so even at full occupancy it produces a submaximal response — acting as an agonist when alone and a functional antagonist when a full agonist is present.
• Pharmacodynamic Antagonism — Diagnose why two co-administered drugs blunt each other by locating the opposition at the receptor or effector rather than at the concentration layer, then classify its binding geometry to read off whether more dose can overcome it.
• Polymerization — The process by which many small monomer units are covalently linked into long chains whose bulk properties emerge from the chain-length distribution rather than from any single monomer's chemistry — the chain, not the monomer, being the unit of analysis.
• Side Reaction — An alternative chemical transformation running in parallel with the desired one, competing for the same substrate through its own rate law, so that selectivity — the ratio of desired rate to the sum of all competing rates — governs yield rather than the desired reaction's absolute speed.